Compare FRAF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | ACRS |
|---|---|---|
| Founded | 1906 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.0M | 311.0M |
| IPO Year | 1995 | 2015 |
| Metric | FRAF | ACRS |
|---|---|---|
| Price | $49.07 | $3.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 16.8K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ 3.39 | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.53 | $1.05 |
| 52 Week High | $57.51 | $4.89 |
| Indicator | FRAF | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 55.72 |
| Support Level | $47.25 | $2.76 |
| Resistance Level | $53.59 | $3.78 |
| Average True Range (ATR) | 1.67 | 0.23 |
| MACD | -0.30 | 0.05 |
| Stochastic Oscillator | 29.69 | 76.26 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.